This is the Healthcare Marketplace Specialization, Healthcare Marketplace Overview. My name is Steve Parente, and we're at Module 5.3.3 Who Owns the Technology? Is it Safe? This is part of our Medical Valuation Overview Segment. So, when we get to this notion of user valuation, there's the thought of going to Physicians and asking them what they would like about this technology fo Mitral valve surgery repair. The advantages are that there's no need for open heart surgery. That's great. Physicians and patients can intervene earlier. Reduced surgery time, less recovery time, and thus much reduced healthcare expenditures give you value back. The disadvantage is that you are not able to perform annuloplasty, which is something that can maybe be able to give you more flexibility for later procedures. Surgical bail-out is very difficult, you may have to do open heart surgery anyway. If they do contend that the adoption of new procedure and also the overpenetration of potentially patients who are asymptomatic, and they may not necessarily need this. So, the current market actually does have other technologies that are in place. A lot of major firms, evalve, Viacor Myocor's turned into Edwards Lifesciences and so, it's not exactly the case that you have a complete clear pathway here in terms of deploying technology. If we do a SWOT analysis for this what we find first of all under strengths is that it's less invasive than surgery. Is there's real-time feedback, it's for early intervention, it could be a pretty good technology, it can lead [INAUDIBLE] disease progression, it can basically get the volume of valve surgeries increased in the US, which would be helpful. The market and repair surgery is increasing, versus replacement. Opportunities are global market, cardiac fissures are all over the place. Growing incidence of MR and interventions. There's an aging population that could be using this as well, it could really improve functionality for certain folks. Possible target for acquisition. More cost effective than most alternatives. And it can complement other technologies. Weaknesses, it's not really intended for ischemic or functional mitral valve problems, Physicians are not really trained to use device, may be more complicated than the current procedure, actually, and we can't perform the annuloplasty. Threats, of course, there's competition out there, substitutions, some clinical trial concerns and just getting into market. Market size is actually pretty substantial. Folks that have this sort of medical condition cardiac wise, we're talking 70 million worldwide. If we actually reduce it down to folks in the developed world that wouldn't have access to such a technology, it'd be about 60% and those that are candidates for the procedure where it would make less sense with the right procedures, it turns out to about an 84,000 person market, very substantial market. This concludes our segment on sizing and the safety of the technology at hand.